ND Biosciences’ publishes a new paper in collaboration with the EPFL and ADX NeuroScience describing thorough characterization of
ND Biosciences was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases
ND Biosciences is an EPFL spinoff that was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases (NDs), such as Parkinson’s and Alzheimer’s Disease.
ND Biosciences has developed unique technologies that allow for the first time reproducing the biochemical, structural, and functional properties of pathological protein aggregates observed in NDs. These unique capabilities are used by ND Biosciences to develop therapies that can prevent the initiation of protein aggregation, and that can clear and neutralize the activities of existing protein aggregates, including their ability to spread and propagate pathology in the brain.
This is accomplished using ND Biosciences’ integrated and proprietary platforms that allow:
1. Reverse-engineering the complexity of disease-relevant protein aggregate targets observed in the brains of patients suffering from NDs under controlled conditions
2. Faithfully recapitulating key processes underlying the formation of protein pathologies and neurodegeneration in a set of validated neuronal models, which ND has developed into an integrated platform for target validation and drug discovery
3. Developing novel companion diagnostic assays and imaging agents that capture the diversity of pathological species detected in biological fluids and brains of patients, for accurate assessment of target engagement and efficacy of ND Biosciences’ novel therapies
The technologies and innovative tools and discovery platforms employed by ND-BioSciences are based on more than 15 years of innovation and pioneering work that was carried out in the laboratory of its founder, Dr. Hilal A. Lashuel and are well-documented in several high impact peer-reviewed publications.
Fares MB, Jagannath S, Lashuel HA. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat Rev Neurosci..
Read More
DeGuire SM, Ruggeri SM,Fares MF,Cendrowska U,Dietler G,and Lashuel HA*. Phosphorylation at S13 and/or S16 strongly inhibits the aggregation of mutant Httex1, ...
Read More
Dikiy I, Fauvet B, Jovičić A, Mahul-Mellier A, Desorby C, El-Turk F, Gitler AD, Lashuel HA*, Eliezer D*. Semisynthetic and in vitro phosphorylation of alpha-synuclein...
Read More
Haj-Yahya M and Lashuel HA*. Protein semisynthesis provides access to Tau disease-associated post-translational modifications (PTMs) and paves the way to....
Read More
Reif A, Chiki A, Ricci J, and Lashuel HA*. Generation of native, untagged Huntingtin Exon1 monomers and fibrils using a SUMO fusion strategy....
Read More
Cariulo C, Azzollini L, Verani M, Martufi P, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh LJ, Lavery D, Doherty E, Conforti P, Cattaneo E, Santimone J, ........
Read More
Lara Petricca, Nour Chiki, Layane Hanna-El-Daher, Lorène Aeschbach, Ritwik Burai, Erik Stoops, Mohamed-Bilal Fares, Hilal A Lashuel
Read More
ND Biosciences’ publishes a new paper in collaboration with the EPFL and ADX NeuroScience describing thorough characterization of
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays
ND-BioSciences Announces partnership with The Michael J. Fox Foundation for parkinson’s research to make available unique synuclein proteoforms
ND BioSciences, a Swiss-based biotechnology company that was
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
La start-up qui veut combattre les maladies neurodégénératives par des traitements novateurs
The biotech start-up based at Biopôle is developing innovative technologies for early diagnostics and therapies
The development of disease models that recapitulate the key pathological and clinical features of neurodegenerative diseases
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
ND BioSciences, a Swiss-based biotechnology company that was